
Sonde Health is a health technology company that has developed a clinically validated vocal biomarker platform. This platform leverages voice-enabled apps and devices to assess and improve mental, cognitive, and respiratory health outcomes. By analyzing over 4,000 vocal features, Sonde's technology can detect subtle changes in voice that signal early health issues. Their API/SDK platform allows organizations to integrate this vocal biomarker analysis into their health initiatives for early detection, risk stratification, and improved engagement. The company emphasizes a proactive approach to healthcare, aiming to enable organizations to provide individuals with engaging ways to detect health conditions earlier. Sonde Health is SOC Type 1 and Type 2 certified and adheres to GDPR and HIPAA regulations.

Sonde Health is a health technology company that has developed a clinically validated vocal biomarker platform. This platform leverages voice-enabled apps and devices to assess and improve mental, cognitive, and respiratory health outcomes. By analyzing over 4,000 vocal features, Sonde's technology can detect subtle changes in voice that signal early health issues. Their API/SDK platform allows organizations to integrate this vocal biomarker analysis into their health initiatives for early detection, risk stratification, and improved engagement. The company emphasizes a proactive approach to healthcare, aiming to enable organizations to provide individuals with engaging ways to detect health conditions earlier. Sonde Health is SOC Type 1 and Type 2 certified and adheres to GDPR and HIPAA regulations.
Core product: Clinically validated vocal biomarker API/SDK for mental, cognitive, and respiratory health
Founded: 2015 or 2016 (company materials reference 2016 spinout; site lists 2015)
Recent funding: Series B $19.25M (Dec 2022); Grant dated Feb 27, 2023
Compliance: SOC Type 1 & Type 2; GDPR and HIPAA adherence
Early detection and monitoring of mental, cognitive and respiratory conditions using voice as a digital biomarker.
2015
Biotechnology
16000000
Series A reported as $16M led by M Ventures
19250000
Series B participants included NEOM Company, KT Corporation, PureTech Health, M Ventures, MP Healthcare Venture Management, Neoteny, Evidity Health Capital
Most recent funding event listed as a Grant on Feb 27, 2023
“Backed by strategic corporate and institutional investors including Partners Investment, NEOM Company, KT Corporation, M Ventures, PureTech Health, MP Healthcare Venture Management, Neoteny, Evidity Health Capital, MassAITC, and the National Institute on Aging”